Drug Research
Elsevier donates Unified Data Model to The Pistoia Alliance, facilitating data sharing and accelerating research in the life sciences
Elsevier, the information analytics business specializing in science and health, has announced it is donating its Unified Data Model (UDM) to The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D....
Drug Research
Nemera receives Drug Manufacturing Authorization for its Neuenburg plant, in Germany
Nemera received from the German Government Drug Administration (Government Presidium, Tübingen) the Pharmaceutical Drug Manufacturing Authorization according to §13 AMG (German Drug & Medicinal Product Law) at its Neuenburg manufacturing facility in Germany. The certification gives...
Drug Research
Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies
Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million. The Series E funding was supported by existing investors including dievini Hopp Biotech holding,...
Drug Research
VarmX Announces Publication in Nature Communications of Groundbreaking Snake Venom Inspired Approach to Restore Blood Clotting in Patients Using Anticoagulants
VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, announced the publication in Nature Communications of a ground breaking LUMC study(1) on modified human factor X as a...
Drug Research
NeuroRx awarded FDA Fast Track Designation for first drug regimen targeting suicide in bipolar depression
NeuroRX , Acute Suicidal Ideation and Behavior (ASIB) , NRX-100 (ketamine HCl) , NRX-100 (ketamine HCl) , NeuroRx, a clinical stage biopharmacompany developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track...
Drug Research
AstraZeneca and Takeda establish collaboration to develop MEDI1341 for Parkinson’s disease
AstraZeneca and Takeda Pharmaceutical Company Limited announced that they have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD). Alpha-synuclein (α-synuclein) is...
Articles
Driving Patient Engagement in Alzheimer’s Disease Clinical Research to Achieve Trial Success
Worldwide, around 47 million people have dementia, and there are 9.9 million new cases every year, according to recent data from the World Health Organization (WHO)1.Alzheimer's disease (AD) is the most common cause of dementia and may contribute to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
